Cargando…
CYP1A2 Genotype Variations Do Not Modify the Benefits and Drawbacks of Caffeine during Exercise: A Pilot Study
Previous investigations have determined that some individuals have minimal or even ergolytic performance effects after caffeine ingestion. The aim of this study was to analyze the influence of the genetic variations of the CYP1A2 gene on the performance enhancement effects of ingesting a moderate do...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372932/ https://www.ncbi.nlm.nih.gov/pubmed/28287486 http://dx.doi.org/10.3390/nu9030269 |
_version_ | 1782518721234862080 |
---|---|
author | Salinero, Juan J. Lara, Beatriz Ruiz-Vicente, Diana Areces, Francisco Puente-Torres, Carlos Gallo-Salazar, César Pascual, Teodoro Del Coso, Juan |
author_facet | Salinero, Juan J. Lara, Beatriz Ruiz-Vicente, Diana Areces, Francisco Puente-Torres, Carlos Gallo-Salazar, César Pascual, Teodoro Del Coso, Juan |
author_sort | Salinero, Juan J. |
collection | PubMed |
description | Previous investigations have determined that some individuals have minimal or even ergolytic performance effects after caffeine ingestion. The aim of this study was to analyze the influence of the genetic variations of the CYP1A2 gene on the performance enhancement effects of ingesting a moderate dose of caffeine. In a double-blind randomized experimental design, 21 healthy active participants (29.3 ± 7.7 years) ingested 3 mg of caffeine per kg of body mass or a placebo in testing sessions separated by one week. Performance in the 30 s Wingate test, visual attention, and side effects were evaluated. DNA was obtained from whole blood samples and the CYP1A2 polymorphism was analyzed (rs762551). We obtained two groups: AA homozygotes (n = 5) and C-allele carriers (n = 16). Caffeine ingestion increased peak power (682 ± 140 vs. 667 ± 137 W; p = 0.008) and mean power during the Wingate test (527 ± 111 vs. 518 ± 111 W; p < 0.001) with no differences between AA homozygotes and C-allele carriers (p > 0.05). Reaction times were similar between caffeine and placebo conditions (276 ± 31 vs. 269 ± 71 milliseconds; p = 0.681) with no differences between AA homozygotes and C-allele carriers. However, 31.3% of the C-allele carriers reported increased nervousness after caffeine ingestion, while none of the AA homozygotes perceived this side effect. Genetic variations of the CYP1A2 polymorphism did not affect the ergogenic effects and drawbacks derived from the ingestion of a moderate dose of caffeine. |
format | Online Article Text |
id | pubmed-5372932 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-53729322017-04-05 CYP1A2 Genotype Variations Do Not Modify the Benefits and Drawbacks of Caffeine during Exercise: A Pilot Study Salinero, Juan J. Lara, Beatriz Ruiz-Vicente, Diana Areces, Francisco Puente-Torres, Carlos Gallo-Salazar, César Pascual, Teodoro Del Coso, Juan Nutrients Article Previous investigations have determined that some individuals have minimal or even ergolytic performance effects after caffeine ingestion. The aim of this study was to analyze the influence of the genetic variations of the CYP1A2 gene on the performance enhancement effects of ingesting a moderate dose of caffeine. In a double-blind randomized experimental design, 21 healthy active participants (29.3 ± 7.7 years) ingested 3 mg of caffeine per kg of body mass or a placebo in testing sessions separated by one week. Performance in the 30 s Wingate test, visual attention, and side effects were evaluated. DNA was obtained from whole blood samples and the CYP1A2 polymorphism was analyzed (rs762551). We obtained two groups: AA homozygotes (n = 5) and C-allele carriers (n = 16). Caffeine ingestion increased peak power (682 ± 140 vs. 667 ± 137 W; p = 0.008) and mean power during the Wingate test (527 ± 111 vs. 518 ± 111 W; p < 0.001) with no differences between AA homozygotes and C-allele carriers (p > 0.05). Reaction times were similar between caffeine and placebo conditions (276 ± 31 vs. 269 ± 71 milliseconds; p = 0.681) with no differences between AA homozygotes and C-allele carriers. However, 31.3% of the C-allele carriers reported increased nervousness after caffeine ingestion, while none of the AA homozygotes perceived this side effect. Genetic variations of the CYP1A2 polymorphism did not affect the ergogenic effects and drawbacks derived from the ingestion of a moderate dose of caffeine. MDPI 2017-03-11 /pmc/articles/PMC5372932/ /pubmed/28287486 http://dx.doi.org/10.3390/nu9030269 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Salinero, Juan J. Lara, Beatriz Ruiz-Vicente, Diana Areces, Francisco Puente-Torres, Carlos Gallo-Salazar, César Pascual, Teodoro Del Coso, Juan CYP1A2 Genotype Variations Do Not Modify the Benefits and Drawbacks of Caffeine during Exercise: A Pilot Study |
title | CYP1A2 Genotype Variations Do Not Modify the Benefits and Drawbacks of Caffeine during Exercise: A Pilot Study |
title_full | CYP1A2 Genotype Variations Do Not Modify the Benefits and Drawbacks of Caffeine during Exercise: A Pilot Study |
title_fullStr | CYP1A2 Genotype Variations Do Not Modify the Benefits and Drawbacks of Caffeine during Exercise: A Pilot Study |
title_full_unstemmed | CYP1A2 Genotype Variations Do Not Modify the Benefits and Drawbacks of Caffeine during Exercise: A Pilot Study |
title_short | CYP1A2 Genotype Variations Do Not Modify the Benefits and Drawbacks of Caffeine during Exercise: A Pilot Study |
title_sort | cyp1a2 genotype variations do not modify the benefits and drawbacks of caffeine during exercise: a pilot study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372932/ https://www.ncbi.nlm.nih.gov/pubmed/28287486 http://dx.doi.org/10.3390/nu9030269 |
work_keys_str_mv | AT salinerojuanj cyp1a2genotypevariationsdonotmodifythebenefitsanddrawbacksofcaffeineduringexerciseapilotstudy AT larabeatriz cyp1a2genotypevariationsdonotmodifythebenefitsanddrawbacksofcaffeineduringexerciseapilotstudy AT ruizvicentediana cyp1a2genotypevariationsdonotmodifythebenefitsanddrawbacksofcaffeineduringexerciseapilotstudy AT arecesfrancisco cyp1a2genotypevariationsdonotmodifythebenefitsanddrawbacksofcaffeineduringexerciseapilotstudy AT puentetorrescarlos cyp1a2genotypevariationsdonotmodifythebenefitsanddrawbacksofcaffeineduringexerciseapilotstudy AT gallosalazarcesar cyp1a2genotypevariationsdonotmodifythebenefitsanddrawbacksofcaffeineduringexerciseapilotstudy AT pascualteodoro cyp1a2genotypevariationsdonotmodifythebenefitsanddrawbacksofcaffeineduringexerciseapilotstudy AT delcosojuan cyp1a2genotypevariationsdonotmodifythebenefitsanddrawbacksofcaffeineduringexerciseapilotstudy |